Skip to main content

Table 2 Adverse events that occurred in more than 10% of 102 patients treated with vinflunine

From: Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice

Adverse event

All treated patients N = 102, N (%)

 

All grades

Grade 3/4

Constipation

72 (70.6%)

6 (5.9%)

Vomiting

50 (49.1%)

2 (2.0%)

Neutropenia

49 (48.1%)

13 (12.8%)

Abdominal pain

35 (34.3%)

5 (4.9%)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us